Agilent Technologies Inc. (NYSE: A) announced the launch of the BioTek Cytation 9 cell imaging multimode reader, combining microplate reading and cell imaging capabilities in a single platform.

The instrument features inverted fluorescence microscopy, upright imaging, and a multimode microplate reader module designed for researchers conducting cell-based and biochemical assays. The company states the device offers twice the imaging speed of previous models and supports workflows from basic research to high-content screening.

The Cytation portfolio was first introduced in 2013. Agilent developed the Cytation 9 based on feedback from existing users to address demands for faster, higher-throughput capabilities in pharmaceutical and biotechnology laboratories.

"Cytation 9 is designed around the same principles, with a broader application range and twice the imaging speed," said Xavier Amouretti, Vice President, BioTek and Seahorse Business Unit Leader at Agilent. "This comes from direct feedback from thousands of Cytation users."

The instrument targets laboratories requiring adaptable tools for cell-based models used in disease and drug discovery research. Agilent reported revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide.

The information is based on a company press release.